TA-001

TA-001 is a potent and selective small molecule inhibitor of phosphodiesterase 4 (PDE4) being developed by Shanghai Thederma for the topical treatment of psoriasis. PDE4 is a key enzyme involved in the degradation of cyclic adenosine monophosphate (cAMP) within immune cells. By inhibiting PDE4, TA-001 elevates intracellular cAMP levels, which subsequently modulates the expression of various pro-inflammatory and anti-inflammatory cytokines, including the inhibition of TNF-α, IL-17, and IL-23. This mechanism helps to resolve the chronic inflammation and keratinocyte hyperproliferation characteristic of psoriatic lesions. Designed as a topical formulation, TA-001 aims to provide effective local therapy with minimal systemic absorption, thereby reducing the risk of gastrointestinal side effects typically associated with oral PDE4 inhibitors.

Other names

TA001TA-001TA 001